The company is a Takeda spinout that touts a new way of mining neuro targets. It originated when Takeda spun out its top neuroscience team in Cambridge, UK. The spinout is described in the article as a transatlantic biotech. The company has attracted outside capital, with a financing reported at $45M. Named investors in the article are GV, Bill Gates and Foresite. The article does not disclose operating metrics or detailed financial terms.

Total raised

$45M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2020